Related Experiment Video
Updated: Jan 31, 2026
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment
Hung Chang1, Yu-Shin Hung2, Wen-Chi Chou2
1Division of Hematology-Oncology, Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kweishan Township, Taoyuan 333, Taiwan; School of Medicine, Chang Gung University, Kweishan Township, Taoyuan Taiwan.
Abstract:
Dasatinib may cause various adverse effects such as myelosuppression and pleural effusion. It is well known that dasatinib may affect cellular immunity, which leads to the subsequent risk of a myriad of infections and viral reactivations, especially cytomegalovirus. Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that typically occurs in immunocompromised hosts. Although pneumonia is not uncommon among dasatinib-treated patients, dasatinib-associated PJP has been reported only once in the literature, without a description of the clinical details. We report herein two cases of PJP in patients receiving treatment containing dasatinib. One patient developed PJP at 7 months following dasatinib in combination with chemotherapy for the treatment of acute lymphoblastic leukemia. The other patient developed pleural effusion and PJP at 2 years following dasatinib treatment for chronic myeloid leukemia. Both patients recovered well after management with sulfamethoxazole/trimethoprim. Our experience illustrates that PJP is a potentially important complication of dasatinib-based treatment. Raising clinical awareness is important as prompt diagnosis and timely management are the cornerstones of successful treatment.
Insights
Dasatinib treatment can increase the risk of Pneumocystis jiroveci pneumonia (PJP), an opportunistic infection. Early diagnosis and treatment with sulfamethoxazole/trimethoprim are crucial for patient recovery.
Area of Science:
- Oncology
- Infectious Diseases
- Pharmacology
Background:
- Dasatinib, a tyrosine kinase inhibitor, is associated with adverse effects including myelosuppression and pleural effusion.
- Dasatinib can impair cellular immunity, increasing susceptibility to infections and viral reactivations, notably cytomegalovirus.
- Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection common in immunocompromised individuals.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
13:27Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:15Receiver Operating Characteristic Plot
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment